Tg Therapeutics (TGTX) Payables (2010 - 2026)

Tg Therapeutics' Payables history runs 17 years deep, the most recent figure standing at $148.8 million for Q1 2026.

• In Q1 2026, Payables rose 429.7% year-over-year to $148.8 million; the TTM figure through Mar 2026 stood at $148.8 million (up 429.7% YoY), while the FY2025 annual figure was $107.5 million, up 84.42% from the prior year.
• Payables for Q1 2026 stood at $148.8 million, up from $107.5 million in the prior quarter.
• The five-year high for Payables was $148.8 million in Q1 2026, with the low at $28.1 million in Q1 2025.
• The 5-year median for Payables is $58.3 million (2024), against an average of $72.2 million.
• The sharpest annual moves came in 2025 and 2026: Payables slumped 67.8% in 2025, then surged 429.7% in 2026.
• Tg Therapeutics' Payables stood at $42.0 million in 2022, then retreated by 8.44% to $38.5 million in 2023, then jumped by 51.53% to $58.3 million in 2024, then jumped by 84.42% to $107.5 million in 2025, then soared by 38.45% to $148.8 million in 2026.
• Business Quant data shows TGTX's Payables at $148.8 million in Q1 2026, $107.5 million in Q4 2025, and $112.3 million in Q3 2025.